A GLP-1 medication used to treat type 2 diabetes and obesity may help cut a person's monthly migraine days by about half, a new study finds.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

“Our findings show liraglutide may be effective for treating stubborn, high-frequency migraines in patients with obesity, and that this effect is independent of weight loss,” the researchers concluded ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...